All In Biotech

Drug Trial Radar · NCT07778498

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Immunogenicity of TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Sep 2029

Study completion Sep 2030

Sponsor

Lead sponsor
Phrontline BiopharmaIndustry
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : • To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ102 • to show preliminary antitumor activity in patients with advanced ovarian or other solid tumors. Participants will: • Receive intravenous (IV) infusions of TJ102 at escalating dose levels (during dose escalation) or at the selected expansion dose. • Undergo regular tumor imaging to assess response. • Provide blood samples for pharmacokinetics (PK) and biomarker analysis. • Be monitored for side effects and overall tolerability. This study is being conducted in adult patients with advanced or metastatic ovarian or other solid tumors who have exhausted standard treatment options.

Conditions

  • Ovarian Cancer

Interventions

  • TJ102Biological

    TJ102 is a CDH6/FRa directed antibody conjugate with dual payloads

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose-limiting toxicitiesTime frame: 2 years
  2. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: 2 years
  3. Number of participants with treatment-related adverse events (TRAEs)Time frame: 2 years

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • South Texas Accelerated Research Therapeutics START LLC

    Los Angeles, California · Recruiting

  • Florida Cancer Specialists Lake Nona

    Orlando, Florida · Recruiting

  • START New York Long Island LLC

    Lake Success, New York · Recruiting

  • Sidney Kimmel Cancer Center Jefferson Health

    Philadelphia, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • NEXT Houston

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • FuDan Unversity Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.